Stockscreener 앱 받기
11.13
2.11%
-0.24
시간 외 거래:
11.13
전일 마감가:
$11.37
열려 있는:
$11.41
하루 거래량:
3.56M
Relative Volume:
0.79
시가총액:
$8.10B
수익:
$125.68M
순이익/손실:
$4.81B
주가수익비율:
1.9699
EPS:
5.65
순현금흐름:
$-781.21M
1주 성능:
-0.36%
1개월 성능:
-5.92%
6개월 성능:
+2.58%
1년 성능:
+11.30%
1일 변동 폭
$11.12
$11.48
1주일 범위
$11.00
$11.48
52주 변동 폭
$9.69
$13.05
Roivant Sciences Ltd Stock (ROIV) Company Profile
명칭
Roivant Sciences Ltd
전화
441-295-5950
주소
CLARENDON HOUSE, 2 CHURCH STREET, HAMILTON HM11
ROIV을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ROIV
Roivant Sciences Ltd
|
11.13 | 8.10B | 125.68M | 4.81B | -781.21M | 5.65 |
|
VRTX
Vertex Pharmaceuticals Inc
|
461.68 | 118.90B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
672.98 | 73.95B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
655.13 | 39.81B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
271.31 | 34.99B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
123.77 | 29.67B | 3.30B | -501.07M | 1.03B | -2.1146 |
Roivant Sciences Ltd Stock (ROIV) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-02-15 | 개시 | Wolfe Research | Outperform |
| 2024-01-05 | 개시 | Piper Sandler | Overweight |
| 2023-12-12 | 개시 | Deutsche Bank | Buy |
| 2023-10-17 | 개시 | Guggenheim | Buy |
| 2023-06-08 | 개시 | BofA Securities | Neutral |
| 2022-10-27 | 개시 | JP Morgan | Overweight |
| 2022-05-23 | 개시 | SVB Leerink | Outperform |
| 2022-04-29 | 개시 | Cantor Fitzgerald | Overweight |
| 2021-12-15 | 개시 | Goldman | Buy |
| 2021-11-08 | 개시 | H.C. Wainwright | Buy |
| 2021-10-28 | 개시 | Citigroup | Buy |
| 2021-10-26 | 개시 | Cowen | Outperform |
| 2021-10-26 | 개시 | Jefferies | Buy |
| 2021-10-26 | 개시 | Truist | Buy |
모두보기
Roivant Sciences Ltd 주식(ROIV)의 최신 뉴스
Roivant Sciences (NASDAQ:ROIV) Upgraded to "Strong-Buy" at Cantor Fitzgerald - MarketBeat
Trump Index: 6 Companies Linked to Trump’s Cabinet Worth Watching - MarketBeat
Trump Index: 6 Companies Linked to Trump's Cabinet Worth Watching - Benzinga
Roivant Sciences Ltd. (NASDAQ:ROIV) Receives Average Rating of "Moderate Buy" from Brokerages - MarketBeat
Roivant sciences president Eric Venker sells $1.13 million in shares - MSN
Zweig DiMenna Associates LLC Takes Position in Roivant Sciences Ltd. (NASDAQ:ROIV) - MarketBeat
Roivant Sciences Ltd. (NASDAQ:ROIV) COO Sells $1,128,000.00 in Stock - MarketBeat
Why Is Andreas Halvorsen Bullish On Roivant Sciences Ltd. (ROIV) Now? - Yahoo Finance
How Rich Is This Indian-Origin Entrepreneur Who Took On Donald Trump But Is Now…? Check His Net Worth - News24
What Is Vivek Ramaswamy’s net worth? The Indian American man who took on Trump and then became a confidante - The Financial Express
Trump Inauguration: Who Is Vivek Ramaswamy and what’s his role in Trump 2.0? - The Financial Express
Roivant Sciences Sees Unusually High Options Volume (NASDAQ:ROIV) - MarketBeat
Roivant Sciences Ltd. Trade Ideas — LS:A3C4MS - TradingView
Roivant sciences increases stake in Immunovant with $336.9 million purchase - Investing.com India
Roivant Sciences Ltd. (NASDAQ:ROIV) Director Acquires $336,900,200.00 in Stock - MarketBeat
Roivant sciences increases stake in Immunovant with $336.9 million purchase By Investing.com - Investing.com Nigeria
Roivant Sciences Ltd. (NASDAQ:ROIV) Shares Acquired by JPMorgan Chase & Co. - Defense World
Is Roivant Sciences (ROIV) the Best Medical Stock to Buy Under $20? - Insider Monkey
12 Best Medical Stocks To Buy Under $20 - Insider Monkey
Nordea Investment Management AB Raises Holdings in Roivant Sciences Ltd. (NASDAQ:ROIV) - MarketBeat
ROIVWroivw Latest Stock News & Market Updates - StockTitan
ROIV Crosses Below Key Moving Average Level - Nasdaq
Arbutus could benefit from Big Pharma bird flu vaccines: Jefferies - MSN
Why Ramaswamy Says America Needs a Cultural Shift Towards Excellence for the Sake of US Students - The Times of India
Roivant Sciences Ltd. (NASDAQ:ROIV) Receives $17.93 Consensus Target Price from Analysts - MarketBeat
Roivant Sciences Ltd. (NASDAQ:ROIV) Given Consensus Recommendation of “Moderate Buy” by Brokerages - Defense World
Why Roivant Sciences Ltd. (ROIV) Is Skyrocketing - Yahoo Finance
10 Firms End 2024 Stronger With Impressive Gains - Insider Monkey
Strategic Sale: Eric Venker Decides To Exercise Options Worth $3.86M At Roivant Sciences - Benzinga
Roivant Sciences Ltd. (NASDAQ:ROIV) COO Sells $2,050,704.16 in Stock - MarketBeat
Insider Selling: Roivant Sciences Ltd. (NASDAQ:ROIV) COO Sells 176,900 Shares of Stock - MarketBeat
Roivant Sciences' president sells common shares worth $4.1 million - Investing.com India
Principal Financial Group Inc. Has $11.65 Million Position in Roivant Sciences Ltd. (NASDAQ:ROIV) - MarketBeat
Roivant Sciences' CIO Mayukh Sukhatme sells $10.6m in shares - Investing.com India
Eric Venker Sells 100,000 Shares of Roivant Sciences Ltd. (NASDAQ:ROIV) Stock - MarketBeat
Insider Selling: Roivant Sciences Ltd. (NASDAQ:ROIV) CIO Sells 689,495 Shares of Stock - MarketBeat
Mayukh Sukhatme Sells 185,946 Shares of Roivant Sciences Ltd. (NASDAQ:ROIV) Stock - MarketBeat
Roivant sciences president Eric Venker sells $1.15 million in shares By Investing.com - Investing.com Nigeria
Roivant Sciences’ CIO Mayukh Sukhatme sells $10.6m in shares By Investing.com - Investing.com Nigeria
Roivant Sciences' CIO Mayukh Sukhatme sells $10.6m in shares By Investing.com - Investing.com South Africa
Roivant sciences president Eric Venker sells $1.15 million in shares - Investing.com
Barclays PLC Buys 75,609 Shares of Roivant Sciences Ltd. (NASDAQ:ROIV) - MarketBeat
Mayukh Sukhatme Sells 412,584 Shares of Roivant Sciences Ltd. (NASDAQ:ROIV) Stock - MarketBeat
Roivant Sciences Ltd (ROIV) 재무 분석
매출
순이익
현금흐름
주당 순 이익
3.95%
2.39%
자본화:
|
볼륨(24시간):